Imugene's Leslie Chong says positive HER-Vaxx data 'validates entire platform', page-242

The release of excellent interim results in the HER-Vaxx Phase 2 trial will speed the recruitment of the rest of the patients required to complete it. As the IDMC now says that a total of only 34 patients is enough (down from 68), only another 7 are required. This shouldn't take long now. Expect final results in the second half of calendar 21.
In the meantime Imugene is evidently moving forward on other fronts. I think we can reasonably expect a positive announcement of some sort before the end of the year - eg first patient dosed with PD1-Vaxx, or complete enrolment for HER-Vaxx Phase 2.
The next announcement that IMO would be likely to put a motor under the share price would be FDA IND clearance for CF33/ Checkvacc. I'd guess we'll hear about that within the next 3-4 months.
But DYOR!